328 related articles for article (PubMed ID: 37398648)
1. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.
Digifico E; Erreni M; Mannarino L; Marchini S; Ummarino A; Anfray C; Bertola L; Recordati C; Pistillo D; Roncalli M; Bossi P; Zucali PA; D'Incalci M; Belgiovine C; Allavena P
Front Immunol; 2023; 14():1116430. PubMed ID: 37398648
[TBL] [Abstract][Full Text] [Related]
2. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
Takeuchi S; Seike M; Noro R; Soeno C; Sugano T; Zou F; Uesaka H; Nishijima N; Matsumoto M; Minegishi Y; Kubota K; Gemma A
Int J Oncol; 2014 Jun; 44(6):1886-94. PubMed ID: 24714722
[TBL] [Abstract][Full Text] [Related]
3. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Canessa PA; Chella A; Lucchi M; Mussi A; Mutti L
Int J Biol Markers; 2010; 25(3):164-70. PubMed ID: 20878622
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.
Ohashi R; Tajima K; Takahashi F; Cui R; Gu T; Shimizu K; Nishio K; Fukuoka K; Nakano T; Takahashi K
Anticancer Res; 2009 Jun; 29(6):2205-14. PubMed ID: 19528482
[TBL] [Abstract][Full Text] [Related]
5. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin is not a specific marker in malignant pleural mesothelioma.
Paleari L; Rotolo N; Imperatori A; Puzone R; Sessa F; Franzi F; Meacci E; Camplese P; Cesario A; Paganuzzi M
Int J Biol Markers; 2009; 24(2):112-7. PubMed ID: 19634115
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
8. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
10. The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.
Laszlo V; Valko Z; Ozsvar J; Kovacs I; Garay T; Hoda MA; Klikovits T; Stockhammer P; Aigner C; Gröger M; Klepetko W; Berger W; Grusch M; Tovari J; Waizenegger IC; Dome B; Hegedus B
J Mol Med (Berl); 2019 Feb; 97(2):231-242. PubMed ID: 30539198
[TBL] [Abstract][Full Text] [Related]
11. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.
Yamamoto J; Ohnuma K; Hatano R; Okamoto T; Komiya E; Yamazaki H; Iwata S; Dang NH; Aoe K; Kishimoto T; Yamada T; Morimoto C
Br J Cancer; 2014 Apr; 110(9):2232-45. PubMed ID: 24743707
[TBL] [Abstract][Full Text] [Related]
12. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
[TBL] [Abstract][Full Text] [Related]
13. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
[No Abstract] [Full Text] [Related]
15. Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System.
Tabata C; Tabata R; Nakano T
Asian Pac J Cancer Prev; 2016; 17(7):3405-9. PubMed ID: 27509983
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells.
Tajima K; Ohashi R; Sekido Y; Hida T; Nara T; Hashimoto M; Iwakami S; Minakata K; Yae T; Takahashi F; Saya H; Takahashi K
Oncogene; 2010 Apr; 29(13):1941-51. PubMed ID: 20101228
[TBL] [Abstract][Full Text] [Related]
17. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
20. FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology.
Chan JM; Chang YC; Chan HC; Chan HC; Chang WC; Wang LF; Tsai TH; Chen YJ; Huang WC
Mol Med; 2024 May; 30(1):73. PubMed ID: 38822233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]